Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE19.3600
- TODAY'S CHANGE (%)0.2600 (1.3613%)
- Bid / Lots17.3300/ 4
- Ask / Lots20.5000/ 2
- Open / Previous Close19.0600 / 19.1000
- Day Range
- 52 Week Range
- Volume308,471
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 1535 | 19.22 |
| 09:36 ET | 200 | 18.96 |
| 09:38 ET | 2175 | 19.06 |
| 09:39 ET | 2269 | 19.17 |
| 09:41 ET | 845 | 19.22 |
| 09:43 ET | 500 | 19.2 |
| 09:45 ET | 100 | 19.2 |
| 09:48 ET | 1977 | 19.185 |
| 09:50 ET | 359 | 19.19 |
| 09:52 ET | 902 | 19.19 |
| 09:54 ET | 801 | 19.185 |
| 09:56 ET | 1322 | 19.24 |
| 09:57 ET | 3400 | 19.23 |
| 10:01 ET | 965 | 19.185 |
| 10:03 ET | 100 | 19.23 |
| 10:06 ET | 160 | 19.205 |
| 10:08 ET | 1600 | 19.22 |
| 10:10 ET | 722 | 19.185 |
| 10:12 ET | 1100 | 19.205 |
| 10:14 ET | 100 | 19.205 |
| 10:15 ET | 206 | 19.195 |
| 10:17 ET | 200 | 19.195 |
| 10:19 ET | 123 | 19.195 |
| 10:26 ET | 337 | 19.185 |
| 10:28 ET | 1047 | 19.1925 |
| 10:30 ET | 265 | 19.18 |
| 10:32 ET | 624 | 19.18 |
| 10:33 ET | 546 | 19.18 |
| 10:35 ET | 3467 | 19.17 |
| 10:37 ET | 756 | 19.135 |
| 10:39 ET | 300 | 19.135 |
| 10:46 ET | 600 | 19.155 |
| 10:48 ET | 1300 | 19.135 |
| 10:50 ET | 100 | 19.14 |
| 10:51 ET | 1100 | 19.115 |
| 10:53 ET | 100 | 19.115 |
| 10:55 ET | 100 | 19.115 |
| 10:57 ET | 700 | 19.13 |
| 11:00 ET | 2408 | 19.03 |
| 11:02 ET | 100 | 19.03 |
| 11:06 ET | 300 | 19.03 |
| 11:08 ET | 300 | 19.09 |
| 11:09 ET | 1004 | 19.13 |
| 11:11 ET | 500 | 19.15 |
| 11:13 ET | 350 | 19.125 |
| 11:15 ET | 700 | 19.14 |
| 11:18 ET | 2101 | 19.22 |
| 11:20 ET | 750 | 19.205 |
| 11:22 ET | 500 | 19.15 |
| 11:24 ET | 800 | 19.155 |
| 11:33 ET | 804 | 19.155 |
| 11:36 ET | 1800 | 19.24 |
| 11:38 ET | 600 | 19.24 |
| 11:40 ET | 200 | 19.215 |
| 11:44 ET | 100 | 19.23 |
| 11:45 ET | 684 | 19.245 |
| 11:49 ET | 100 | 19.27 |
| 11:51 ET | 991 | 19.365 |
| 11:54 ET | 387 | 19.33 |
| 11:58 ET | 1200 | 19.32 |
| 12:00 ET | 1312 | 19.29 |
| 12:02 ET | 1500 | 19.21 |
| 12:03 ET | 900 | 19.22 |
| 12:05 ET | 1000 | 19.23 |
| 12:12 ET | 100 | 19.25 |
| 12:14 ET | 300 | 19.22 |
| 12:16 ET | 900 | 19.225 |
| 12:20 ET | 1159 | 19.21 |
| 12:21 ET | 583 | 19.245 |
| 12:25 ET | 100 | 19.245 |
| 12:27 ET | 100 | 19.22 |
| 12:32 ET | 800 | 19.245 |
| 12:34 ET | 100 | 19.22 |
| 12:36 ET | 1601 | 19.21 |
| 12:39 ET | 1257 | 19.23 |
| 12:41 ET | 100 | 19.19 |
| 12:43 ET | 600 | 19.24 |
| 12:45 ET | 100 | 19.2 |
| 12:48 ET | 100 | 19.19 |
| 12:56 ET | 600 | 19.2047 |
| 12:57 ET | 1100 | 19.2 |
| 12:59 ET | 100 | 19.205 |
| 01:01 ET | 436 | 19.235 |
| 01:08 ET | 1200 | 19.21 |
| 01:10 ET | 2100 | 19.25 |
| 01:14 ET | 1400 | 19.21 |
| 01:15 ET | 200 | 19.2 |
| 01:19 ET | 447 | 19.15 |
| 01:21 ET | 208 | 19.09 |
| 01:26 ET | 300 | 19.1 |
| 01:30 ET | 100 | 19.07 |
| 01:32 ET | 720 | 19.09 |
| 01:35 ET | 557 | 19.06 |
| 01:37 ET | 400 | 19.06 |
| 01:39 ET | 971 | 19.06 |
| 01:44 ET | 100 | 19.06 |
| 01:46 ET | 100 | 19.1 |
| 01:50 ET | 100 | 19.08 |
| 01:53 ET | 700 | 19.12 |
| 01:57 ET | 1010 | 19.18 |
| 02:00 ET | 100 | 19.16 |
| 02:02 ET | 600 | 19.18 |
| 02:04 ET | 17327 | 19.29 |
| 02:06 ET | 100 | 19.275 |
| 02:08 ET | 500 | 19.28 |
| 02:09 ET | 100 | 19.26 |
| 02:15 ET | 500 | 19.26 |
| 02:18 ET | 100 | 19.25 |
| 02:20 ET | 847 | 19.28 |
| 02:24 ET | 100 | 19.25 |
| 02:26 ET | 1552 | 19.21 |
| 02:27 ET | 328 | 19.21 |
| 02:29 ET | 100 | 19.21 |
| 02:31 ET | 2100 | 19.21 |
| 02:36 ET | 300 | 19.24 |
| 02:38 ET | 485 | 19.2 |
| 02:40 ET | 800 | 19.23 |
| 02:45 ET | 3700 | 19.2 |
| 02:47 ET | 800 | 19.24 |
| 02:54 ET | 100 | 19.23 |
| 02:56 ET | 1500 | 19.21 |
| 02:58 ET | 1000 | 19.25 |
| 03:00 ET | 400 | 19.25 |
| 03:02 ET | 300 | 19.245 |
| 03:03 ET | 200 | 19.23 |
| 03:07 ET | 638 | 19.275 |
| 03:09 ET | 700 | 19.27 |
| 03:14 ET | 256 | 19.27 |
| 03:16 ET | 1300 | 19.23 |
| 03:18 ET | 551 | 19.21 |
| 03:20 ET | 300 | 19.22 |
| 03:21 ET | 600 | 19.21 |
| 03:23 ET | 964 | 19.26 |
| 03:25 ET | 138 | 19.24 |
| 03:27 ET | 552 | 19.23 |
| 03:30 ET | 100 | 19.26 |
| 03:32 ET | 413 | 19.25 |
| 03:34 ET | 515 | 19.27 |
| 03:36 ET | 100 | 19.28 |
| 03:38 ET | 736 | 19.27 |
| 03:39 ET | 200 | 19.27 |
| 03:41 ET | 700 | 19.28 |
| 03:43 ET | 4187 | 19.28 |
| 03:45 ET | 1200 | 19.3 |
| 03:48 ET | 1014 | 19.3 |
| 03:50 ET | 1646 | 19.33 |
| 03:52 ET | 2100 | 19.42 |
| 03:54 ET | 4661 | 19.415 |
| 03:56 ET | 5739 | 19.42 |
| 03:57 ET | 4774 | 19.36 |
| 03:59 ET | 67788 | 19.36 |
Jun 24, 2024
Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis, from 8:00AM ET on Monday Jun 24, 2024 by Dow Jones
8:00AM ET on Monday Jun 24, 2024 by Dow Jones
Jun 17, 2024
Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative, from 8:30AM ET on Monday Jun 17, 2024 by Dow Jones
8:30AM ET on Monday Jun 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.4B | 227.2x | --- |
Dynavax Technologies Corp | 1.5B | 225.2x | --- |
Zai Lab Ltd | 1.7B | -4.9x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -6.1x | --- |
MannKind Corp | 1.4B | 219.0x | --- |
Maravai LifeSciences Holdings Inc | 1.8B | -7.0x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President, Chief Commercial Officer
- Ross Moat
- Senior Vice President, Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 227.2x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | 126.5x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
